Skip to main content
. 2013 Sep 3;54(9):5937–5943. doi: 10.1167/iovs.13-12326

Figure 1. .

Figure 1. 

KZ-41 protects REC against melphalan-induced apoptosis without affecting Y79 retinoblastoma cells. (A) Cell Death ELISA results for REC treated with nothing (control), melphalan (4 μg/mL) and melphalan + various doses of KZ-41. *P < 0.05 versus control. #P < 0.05 versus melphalan only. n = 4. (B) Cell Death ELISA on Y79 retinoblastoma cells with no treatment (control), 0.8 μg/mL, 1 μg/mL, or 4 μg/mL melphalan to demonstrate that melphalan best induces apoptosis at 4 μg/ml. (C) Cell Death ELISA on Y79 retinoblastoma cells treated with melphalan at 4 μg/mL alone or in combination with KZ-41, a novel quinic acid derivative. KZ-41 did not inhibit melphalan-induced apoptosis of Y79 cells. *P < 0.05 versus control. #P < 0.05 versus melphalan only. Data are mean ± SEM. n = 4.